PMID- 30760061
OWN - NLM
STAT- MEDLINE
DCOM- 20200306
LR  - 20200306
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 11
IP  - 6
DP  - 2019 Apr
TI  - Delayed IL-21 treatment preferentially expands peptide-specific CD8(+) T cells by 
      reducing bystander activation of T cells.
PG  - 497-513
LID - 10.2217/imt-2018-0095 [doi]
AB  - AIM: We previously reported a simple and practical procedure to generate 
      peptide-specific CD8(+) T cells using peptide and IL-2, which is applied to 
      produce human telomerase reverse transcriptase (hTERT)-specific CD8+ T cells for 
      clinical use. We have modified the procedure to enhance the amplification of 
      peptide-specific CD8(+) T cells adding IL-21. MATERIALS & METHODS: Using human 
      leukocyte antigen (HLA)-A*0201-restricted cytomegalovirus/pp65-specific CD8(+) T 
      cells of healthy volunteers, we optimized the culture conditions by adjusting the 
      dose and timing of IL-21 treatment. RESULTS & CONCLUSION: By adding IL-21, we 
      accelerated the expansion rate of cytomegalovirus/pp65-specific CD8(+) T cells by 
      reducing bystander activation of T cells. We expect that the procedure including 
      IL-21 would improve the production rate of hTERT- and Wilms tumor 1 
      (WT1)-specific CD8(+) T cells for clinical trials.
FAU - Kim, Seon-Hee
AU  - Kim SH
AD  - Immunotherapeutics Branch, Division of Convergence Technology, National Cancer 
      Center, Goyang, 10408 Korea.
FAU - Park, Sang-Yoon
AU  - Park SY
AD  - Common Cancer Branch, Division of Clinical Research, National Cancer Center, 
      Goyang, 10408 Korea.
AD  - Center for Uterine Cancer, National Cancer Center, Goyang, 10408 Korea.
FAU - Lim, Myong Cheol
AU  - Lim MC
AD  - Center for Uterine Cancer, National Cancer Center, Goyang, 10408 Korea.
AD  - Cancer Healthcare Research Branch, Division of Cancer Epidemiology & Management, 
      National Cancer Center, Goyang, 10408 Korea.
FAU - Lee, Eun Sook
AU  - Lee ES
AD  - Immunotherapeutics Branch, Division of Convergence Technology, National Cancer 
      Center, Goyang, 10408 Korea.
AD  - Center for Breast Cancer, National Cancer Center, Goyang, 10408 Korea.
FAU - Lee, Eun Gyeong
AU  - Lee EG
AD  - Center for Breast Cancer, National Cancer Center, Goyang, 10408 Korea.
FAU - Han, Seoung-Eun
AU  - Han SE
AD  - Immunotherapeutics Branch, Division of Convergence Technology, National Cancer 
      Center, Goyang, 10408 Korea.
FAU - Kim, Young-Ho
AU  - Kim YH
AD  - Rare Cancer Branch, Division of Clinical Research, National Cancer Center, 
      Goyang, 10408, Korea.
FAU - Kwon, Byoung S
AU  - Kwon BS
AD  - Eutilex, Co., Ltd, Suite# 1401 Daeryung Technotown 17 Gasan digital 1-ro 25, 
      Geumcheon-gu, Seoul 08594, Korea.
AD  - Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 
      70112, USA  Center for Breast Cancer, National Cancer Center, Goyang, 10408 
      Korea.
FAU - Choi, Beom K
AU  - Choi BK
AD  - Biomedicine Production Branch, National Cancer Center, Goyang, 10408 Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190214
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Interleukins)
RN  - 0 (Peptides)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (cytomegalovirus matrix protein 65kDa)
RN  - MKM3CA6LT1 (interleukin-21)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Bystander Effect
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - HLA-A2 Antigen/metabolism
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Interleukins/*metabolism
MH  - Lymphocyte Activation
MH  - Neoplasms/immunology/*therapy
MH  - Peptides/immunology/metabolism
MH  - Protein Binding
MH  - T-Cell Antigen Receptor Specificity
MH  - Viral Matrix Proteins/immunology/metabolism
OTO - NOTNLM
OT  - 4-1BB
OT  - CD137
OT  - CD8 T cells
OT  - IL-21
OT  - immunotherapy
OT  - tumor-associated antigen
EDAT- 2019/02/15 06:00
MHDA- 2020/03/07 06:00
CRDT- 2019/02/15 06:00
PHST- 2019/02/15 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/02/15 06:00 [entrez]
AID - 10.2217/imt-2018-0095 [doi]
PST - ppublish
SO  - Immunotherapy. 2019 Apr;11(6):497-513. doi: 10.2217/imt-2018-0095. Epub 2019 Feb 
      14.